What Ingenes does

Ingenes (legal name Instituto de Infertilidad y Genética México, S.C.) is a Mexico City-headquartered fertility institute founded in 2005 by Dr. Felipe Camargo, operating 20+ owned clinics across Mexico (Mexico City, Monterrey, Guadalajara, Querétaro, Mérida, Tijuana, Puebla) and the United States (San Diego, McAllen/Edinburg, Houston, Orange County) with 501–1,000 employees. The company provides assisted reproduction services — IVF, ICSI, PICSI, artificial insemination, egg/sperm donation and preservation, surrogacy, and maternal-fetal care — to heterosexual couples, LGBTQ+ couples, single individuals and international medical tourists from 40+ countries, reporting 75,000+ babies born cumulatively. Its differentiator is the proprietary TripleMed® platform, which integrates reproductive medicine with regenerative/genetic medicine (Ovagen® ovarian regeneration, Endogen® endometrial restoration, IVF MORE® mitochondrial restoration, Procelk® exosome therapy, PGT-A/PGT-M genetic testing, Eligender® sex selection, Clarix® NIPT) and metabolic medicine (Longevity Test, personalized ketogenic nutrition) under a single clinical roof. The business model combines fee-for-service treatment packages — closed-price multi-cycle programs with a partial money-back guarantee — with a B2B corporate wellness channel covering 500+ multinational employers and a 1,000+ referring-physician network. International patient services are coordinated through virtual consultations, travel logistics and multilingual follow-up. Ingenes is privately held with no disclosed external funding; Cofepris license, REDLARA Gold lab certification, ASRM and ESHRE affiliations provide regulatory anchoring, and US operations operate under HIPAA as a unified business unit.

Name

Ingenes

Legal name

Instituto de Infertilidad y Genética México, S.C.

Website

https://ingenes.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Ingenes is a Mexico-headquartered fertility institute operating 20+ clinics across Mexico and the United States, delivering IVF, regenerative and genetic reproductive medicine, and surrogacy programs to individuals, couples and medical tourists from 40+ countries.

Ownership category

akta.pro rank

Product category

Fertility and Reproductive Medicine Services

NAICS

Family Planning Centers (621410)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD)

akta.pro secondary industries

Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC), Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation) (HLALAHAA)

Keywords

• Fertility treatments
• Assisted reproduction
• In vitro fertilization
• Reproductive medicine
• Surrogacy services

Headquarters

HQ city

Mexico City

HQ country

Mexico

HQ region

Latin America

Offices11 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Medical Treatment Services: Ingenes generates revenue primarily through fee-for-service medical treatments including IVF, ICSI, insemination, surrogacy programs, egg/sperm preservation, donation programs, and maternal-fetal care. Treatments are sold as multi-cycle program packages with closed pricing (multiple cycles included in one price), with medication, studies, and procedures bundled.
2. Multi-Cycle Programs with Money-Back Guarantee: Multi-cycle program bundles with partial refund if pregnancy is not achieved after contracted cycles. This de-risks the patient purchase decision and drives conversion for high-complexity treatments.
3. Corporate Wellness Agreements: Over 500 multinational corporations purchase preferential access to Ingenes fertility benefits for their employees under corporate agreements, providing a B2B revenue stream.
4. International / Medical Tourism: Patients from more than 40 countries travel to Ingenes locations in Mexico and the US, generating international patient revenue with coordinated travel, treatment, and follow-up services.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

Ingenes operates a network of fertility clinics providing assisted reproduction treatments (IVF, ICSI, PICSI, artificial insemination), egg and sperm donation and preservation, surrogacy programs, and proprietary regenerative therapies (Ovagen®, Endogen®, IVF MORE®, Procelk®) under its integrated TripleMed® platform combining reproductive, regenerative/genetic, and metabolic medicine. It serves individual patients and couples (heterosexual, LGBTQ+, single) via 20+ branches in Mexico and the US, with closed-price multi-cycle packages and corporate wellness agreements.

Product overview

Ingenes is a reproductive health institute offering a comprehensive portfolio of assisted reproduction and fertility treatments, organized around its proprietary TripleMed® approach that integrates reproductive medicine, regenerative and genetic medicine, and metabolic medicine. The core offerings include FIV/ICSI/PICSI treatments, artificial insemination, egg and sperm donation services, fertility preservation, and the IVF MORE® mitochondrial restoration technique. Specialized services encompass genetic testing (PGT-A, PGT-M), sex selection (Eligender®), stem cell therapies (Ovagen®, Endogen®, Procelk®), and surrogacy programs. The institute operates 20+ branches across Mexico and the United States, serving patients from over 40 countries.

Differentiator

Problem solved

Functional benefit

Brands

• TripleMed®: Proprietary integrated medicine approach combining reproductive medicine, regenerative and genetic medicine, and metabolic medicine under one roof.
• Ovagen®
• Endogen®
• Procelk®
• IVF MORE®
• Eligender®
• Clarix®

Products and services

• TripleMed® Integrated Fertility Program Comprehensive fertility treatment program integrating reproductive medicine (IVF, ICSI, insemination, surrogacy), regenerative and genetic medicine (stem cells, PGT-A/PGT-M, sex selection), and metabolic medicine (longevity testing, personalized nutritional intervention) for individuals and couples facing complex infertility.
• In Vitro Fertilization (FIV) High-complexity assisted reproduction procedure for couples facing infertility challenges, including gamete retrieval, fertilization in laboratory, and embryo transfer.
• FIV with ICSI IVF with intracytoplasmic sperm injection (ICSI), where a single sperm is directly injected into an egg for severe male factor infertility cases.
• FIV with PICSI IVF with physiological ICSI (PICSI), selecting mature sperm based on hyaluronic acid binding to improve fertilization outcomes.
• Artificial Insemination Low-complexity assisted reproduction treatment involving timed intrauterine insemination for patients with compatible infertility profiles.
• Egg Donation (Ovodonación) Egg donation service using donor eggs for patients who cannot use their own eggs, accessed through the Mexican egg bank.
• Sperm Donation Sperm donation service for patients requiring donor sperm, sourced from the Mexican and international sperm banks.
• Egg Preservation Egg preservation (egg freezing) service for women delaying childbearing for social, oncological, or gender-transition-related reasons.
• Sperm Preservation Sperm cryopreservation service for men, including those facing medical treatments affecting fertility.
• Ovagen® Ovarian Regeneration Proprietary ovarian tissue regeneration therapy using stem cells, targeting women with low ovarian reserve including those aged 38–45 told their eggs are no longer viable.
• Endogen® Endometrial Regeneration Proprietary endometrial regeneration therapy using stem cells to restore a damaged endometrium to receptivity for implantation in patients with failed IVF cycles.
• IVF MORE® Egg Mitochondrial Restoration Proprietary mitochondrial restoration therapy that rejuvenates eggs at the mitochondrial level, offered to patients with multiple failed IVF attempts and no clear answers.
• Procelk® Exosome-Based Stem Cell Therapy Proprietary exosome-based therapy applied to enhance gamete and embryo quality, used as part of the regenerative medicine branch within TripleMed.
• PGT-A Preimplantation Genetic Testing Preimplantation genetic testing for aneuploidy (PGT-A) to screen embryos for chromosomal abnormalities before transfer.
• PGT-M Preimplantation Genetic Testing Preimplantation genetic testing for monogenic disorders (PGT-M) to screen embryos for specific inherited genetic conditions before transfer.
• Eligender® Sex Selection Sex selection service using genetic testing to choose the sex of the embryo for family balancing, offered as an additional service within the TripleMed framework.
• Clarix® Non-Invasive Prenatal Test

Quantifiable outcome

• 75,000+ babies born over 20 years of operation
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Two partnerships are on record, tiered core.

• 500+ Multinational Corporations (Corporate Wellness Partners)coreChannel Partner/ Reseller/ DistributorOver 500 multinational corporations have corporate agreements with Ingenes that include fertility medicine benefits for their teams. These agreements provide employees with preferential access, special conditions, and integral support for treatments including IVF, preservation, donation, and surrogacy.
• 1,000+ Referring Physicians (gynecologists, endocrinologists, specialists)coreChannel Partner/ Reseller/ DistributorMore than 1,000 gynecologists, endocrinologists, and specialists refer patients to Ingenes from multiple countries. Ingenes works as a team with the treating physician, coordinates treatment, and returns the patient with complete follow-up to the referring doctor.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Boston IVF: US-based fertility clinic network offering IVF, ICSI, PGT, and preservation across multiple sites. Comparable as a multi-clinic fertility operator with outcomes reporting, though more concentrated in the US than Ingenes' Mexico/US model.
• Shady Grove Fertility: Major US fertility chain (part of Unified Women's Healthcare) with shared-risk and multi-cycle refund programs that closely mirror Ingenes' Programas Multiciclo structure, making it a direct comparator on outcomes-based pricing and employer benefit partnerships.
• Reproductive Medicine Associates of New Jersey (RMANJ): Large US fertility practice group with high-volume outcomes reporting and PGT-focused programs. Comparable on outcome transparency, multi-clinic fertility operations, and integration of advanced genetic testing into the standard IVF pathway.
• CCRM (Colorado Center for Reproductive Medicine): Large US fertility clinic network with proprietary lab protocols and aggressive expansion. Comparable on integrated reproductive + genetic medicine positioning and on multi-site specialty fertility model, though without Ingenes' regenerative medicine and medical tourism angles.

Direct peers

• Instituto Valenciano de Infertilidad (IVI): Pioneering Spanish fertility institute that pioneered many techniques now standard across the industry; comparable to Ingenes on research-driven positioning, multi-country footprint, and international patient focus.
• New Hope Fertility Center: US fertility clinic known for mild/mini-IVF protocols and high-volume international patient flow. Comparable to Ingenes on medical tourism orientation and on serving complex or repeat-failure patient cases.
• IVI-RMA Global: World's largest fertility clinic network (now under KKR ownership) offering IVF, ICSI, PGT, egg donation, and preservation across Europe, Latin America, and beyond. Most directly comparable to Ingenes as a multi-country fertility chain with strong medical tourism and B2B employer channels.
• Eugin: European fertility chain (formerly part of the NMC group) with cross-border patient flow from Latin America, including egg donation programs and multi-cycle packages. Comparable to Ingenes as a cross-border fertility operator with strong Latin American demand.

Regional players

• Genea: Australian fertility clinic and technology provider operating a multi-site network across Australia and selected international markets. Comparable on clinic-network scale and proprietary lab/embryology investments, though regional.
• ProcreaTec: Madrid-based fertility clinic catering significantly to international patients, particularly from Latin America and the Middle East. Comparable to Ingenes on cross-border medical tourism and premium positioning, though serving European rather than Mexican capacity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ingenes
• Facebookfacebook.com/ingenesinstitute

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ingenes